The Global anti-viral market entails a wide variety of diseases and pandemic disruptions, varying from year to year. This fact sheet will focus on a few of the major markets within the overall market as an overview.
Major markets that can stand alone within this category include:
2010 - $22 billion
Truveda, Valtrex and Atripla were the leading antiviral agents in 2011.
178 companies that are involved in developing various technologies and products are profiled and with 161 collaborations. These include major pharmaceutical companies (13), those developing antiviral therapeutics (107) as well as viral vaccine companies (58).
Leaders include: Gilead, GalaxoSmithKline, Merck, BMS (including acquisition of DuPont Pharmaceutical) and Abbott
Technology Approaches: Pharmaceuticals and molecular biological therapies such as gene therapy and RNA interference (RNAi) as well as vaccines for virus infections; NanoViricides are polymeric micelles, which act as nanomedicines to destroy viruses. Various methods for local as well as systemic delivery of antiviral agents and vaccines exist. Nanobiotechnology plays an important role in improving delivery of antivirals. Advantages and limitations of delivery of gene-based, antisense and RNAi antiviral therapeutics.
In 2010, the global antivirals market was estimated to be worth $22.1 billion and is expected to reach revenues of approximately $30.1 billion by 2017 at a CAGR of 4.5% between 2010 and 2017. Overall antiviral market is driven by Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) therapeutic sales which accounted for 61% of the market 2010. The Research and Development (R&D) pipeline appears moderately strong with 483 molecules, 33% of which are in Phase II.
Toxicities are emerging as major treatment challenges